ATE300959T1 - Formulierungen enthaltend antisense nukleotide spezifisch für connexine - Google Patents

Formulierungen enthaltend antisense nukleotide spezifisch für connexine

Info

Publication number
ATE300959T1
ATE300959T1 AT00901236T AT00901236T ATE300959T1 AT E300959 T1 ATE300959 T1 AT E300959T1 AT 00901236 T AT00901236 T AT 00901236T AT 00901236 T AT00901236 T AT 00901236T AT E300959 T1 ATE300959 T1 AT E300959T1
Authority
AT
Austria
Prior art keywords
connexine
formulations containing
antisense nucleotides
containing antisense
nucleotides specific
Prior art date
Application number
AT00901236T
Other languages
English (en)
Inventor
David Laurence Becker
Colin Richard Green
Original Assignee
Becker David Dr
Green Colin R Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Becker David Dr, Green Colin R Dr filed Critical Becker David Dr
Application granted granted Critical
Publication of ATE300959T1 publication Critical patent/ATE300959T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
AT00901236T 1999-01-27 2000-01-27 Formulierungen enthaltend antisense nukleotide spezifisch für connexine ATE300959T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NZ33392899 1999-01-27
NZ50019099 1999-10-07
PCT/GB2000/000238 WO2000044409A1 (en) 1999-01-27 2000-01-27 Formulations comprising antisense nucleotides to connexins

Publications (1)

Publication Number Publication Date
ATE300959T1 true ATE300959T1 (de) 2005-08-15

Family

ID=26652011

Family Applications (2)

Application Number Title Priority Date Filing Date
AT00901236T ATE300959T1 (de) 1999-01-27 2000-01-27 Formulierungen enthaltend antisense nukleotide spezifisch für connexine
AT05016736T ATE533515T1 (de) 1999-01-27 2000-01-27 Formulierungen enthaltend antisense nukleotide spezifisch für connexine

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT05016736T ATE533515T1 (de) 1999-01-27 2000-01-27 Formulierungen enthaltend antisense nukleotide spezifisch für connexine

Country Status (13)

Country Link
US (11) US7098190B1 (de)
EP (3) EP2314321B1 (de)
JP (4) JP4994533B2 (de)
AT (2) ATE300959T1 (de)
AU (1) AU776512B2 (de)
CA (2) CA2361251C (de)
CY (2) CY1112557T1 (de)
DE (1) DE60021700T2 (de)
DK (3) DK1146908T3 (de)
ES (3) ES2377749T3 (de)
NZ (1) NZ513154A (de)
PT (3) PT2314321E (de)
WO (1) WO2000044409A1 (de)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5991308A (ja) * 1982-11-16 1984-05-26 Kawasaki Heavy Ind Ltd 平面の検出方法
WO2000044409A1 (en) * 1999-01-27 2000-08-03 University College London Formulations comprising antisense nucleotides to connexins
EP1197553A1 (de) * 2000-10-12 2002-04-17 A3D GmbH, Antisense Design & Drug Development Antisense-Nukleinsäure gegen das alphaV Integrin
US20050119211A1 (en) * 2001-05-18 2005-06-02 Sirna Therapeutics, Inc. RNA mediated inhibition connexin gene expression using short interfering nucleic acid (siNA)
EA015670B9 (ru) * 2003-12-03 2012-01-30 Коуда Терапьютикс (Нз) Лтд. Антисмысловые соединения, нацеленные на коннексины, и способы их применения
EP1827480B1 (de) 2004-12-21 2016-11-09 MUSC Foundation For Research Development Zusammensetzungen und methoden zur wundheilung und geweberegenerierung
US9408381B2 (en) 2004-12-21 2016-08-09 Musc Foundation For Research Development Alpha Connexin c-Terminal (ACT) peptides for use in transplant
WO2008157840A2 (en) * 2007-06-21 2008-12-24 Musc Foundation For Research Development Alpha connexin c-terminal (act) peptides for treating age-related macular degeneration
US9248141B2 (en) 2005-02-03 2016-02-02 Coda Therapeutics, Inc. Methods of treatment by administering anti-connexin proteins and mimetics
US20090163432A1 (en) * 2005-11-08 2009-06-25 Kansai Technology Licensing Organization Co., Ltd. Therapeutic Agent for Corneal Diseases
WO2007087113A2 (en) 2005-12-28 2007-08-02 The Scripps Research Institute Natural antisense and non-coding rna transcripts as drug targets
JP2010507387A (ja) 2006-10-25 2010-03-11 クアーク・ファーマスーティカルス、インコーポレイテッド 新規のｓｉＲＮＡおよびその使用方法
KR20100027091A (ko) * 2006-11-15 2010-03-10 코다 테라퓨틱스, 인크. 상처 치유를 위한 개선 방법 및 조성물
AU2014204482B2 (en) * 2006-12-11 2016-07-07 Coda Therapeutics, Inc. Anticonnexin polynucleotides as impaired wound healing compositions
DK2101791T3 (en) 2006-12-11 2015-01-05 Coda Therapeutics Inc ANTICONNEXIN POLYNUCLEOTIDES AS COMPOSITIONS AGAINST DEGRADED HEALTH
JP5646997B2 (ja) 2007-10-03 2014-12-24 クォーク ファーマシューティカルズ インコーポレーティッドＱｕａｒｋ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 新規ｓｉＲＮＡ構造
WO2009075881A2 (en) 2007-12-11 2009-06-18 Coda Therapeutics, Inc. Impaired wound healing compositions and treatments
US20100279921A1 (en) * 2007-12-11 2010-11-04 Coda Therapeutics, Inc. Impaired wound healing compositions and treatments
AU2008343754A1 (en) * 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Use of anti-connexin polynucleotides for the treatment of surgical adhesions
JP2011507861A (ja) * 2007-12-21 2011-03-10 コーダ セラピューティクス， インコーポレイテッド 線維症性の状態の治療のための抗コネキシンポリヌクレオチド剤と組み合わせた抗コネキシンポリペプチド剤の使用
CA2710380A1 (en) * 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Use of anti-connexin 43 poly nucleotide for the treatment of fibrotic conditions
US20110245184A1 (en) * 2007-12-21 2011-10-06 Bradford James Duft Treatment of surgical adhesions
WO2009085277A2 (en) * 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Treatment of abnormal or excessive scars
WO2009085269A2 (en) * 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Use of anti-connexin polynucleotides, peptides or antibodies for the treatment of orthopedic conditions
CA2710386A1 (en) 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Improved medical devices
EP2252320A2 (de) * 2007-12-21 2010-11-24 Coda Therapeutics, Inc. Verwendung von anti-connexin-polynucleotiden und peptiden zur behandlung von auffälligen oder übermässigen narben
US20110243964A1 (en) * 2007-12-21 2011-10-06 Bradford James Duft Treatment of orthopedic conditions
US20110038920A1 (en) * 2008-01-07 2011-02-17 Ryoichi Mori Wound healing compositions and treatments
US10138485B2 (en) 2008-09-22 2018-11-27 Rxi Pharmaceuticals Corporation Neutral nanotransporters
ES2727549T3 (es) 2008-10-03 2019-10-17 Curna Inc Tratamiento de las enfermedades relacionadas con la apolipoproteína a1 por inhibición del transcrito antisentido natural a la apolipoproteína a1
ES2600781T3 (es) 2008-12-04 2017-02-10 Curna, Inc. Tratamiento para enfermedades relacionadas con el factor de crecimiento del endotelio vascular (vegf) mediante la inhibición de transcritos antisentido naturales de vegf
KR101829469B1 (ko) 2008-12-04 2018-03-30 큐알엔에이, 인크. Ｅｐｏ에 대한 천연 안티센스 전사체의 억제에 의해 에리트로포에틴(ｅｐｏ) 관련된 질환의 치료
JP5923306B2 (ja) 2008-12-04 2016-05-24 クルナ・インコーポレーテッド 腫瘍抑制遺伝子に対する天然アンチセンス転写物の抑制による腫瘍抑制遺伝子関連疾患の治療
US8669941B2 (en) * 2009-01-05 2014-03-11 Nuance Communications, Inc. Method and apparatus for text entry
WO2010093904A2 (en) 2009-02-12 2010-08-19 Curna, Inc. Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
EP2408919B1 (de) 2009-03-16 2017-10-18 CuRNA, Inc. Behandlung von erkrankungen im zusammenhang mit dem nuklearfaktor (erythroid-derived)-like 2 (nrf2) mittels hemmung des natürlichen antisense-transkripts gegen nrf2
ES2627763T3 (es) 2009-03-17 2017-07-31 Curna, Inc. Tratamiento de enfermedades relacionadas con el homólogo tipo delta 1 (dlk1) por inhibición de transcrito antisentido natural a dlk1
CN102459596B (zh) 2009-05-06 2016-09-07 库尔纳公司 通过针对脂质转运和代谢基因的天然反义转录物的抑制治疗脂质转运和代谢基因相关疾病
JP6250930B2 (ja) 2009-05-06 2017-12-20 クルナ・インコーポレーテッド トリステトラプロリン（ｔｔｐ）に対する天然アンチセンス転写物の抑制によるｔｔｐ関連疾患の治療
EP2427554B1 (de) 2009-05-08 2016-11-16 CuRNA, Inc. Behandlung von dystrophin-bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts gegen die dmd-familie
CN102575251B (zh) 2009-05-18 2018-12-04 库尔纳公司 通过抑制针对重编程因子的天然反义转录物来治疗重编程因子相关的疾病
JP2012527248A (ja) 2009-05-22 2012-11-08 クルナ・インコーポレーテッド 転写因子ｅ３（ｔｆｅ３）に対する天然アンチセンス転写物の阻害によるｔｆｅ３およびインスリン受容体基質２（ｉｒｓ２）関連疾患の処置
KR101704988B1 (ko) 2009-05-28 2017-02-08 큐알엔에이, 인크. 항바이러스 유전자에 대한 천연 안티센스 전사체의 억제에 의한 항바이러스 유전자 관련된 질환의 치료
WO2010148050A2 (en) 2009-06-16 2010-12-23 Curna, Inc. Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene
CA2765509C (en) 2009-06-16 2021-08-17 Joseph Collard Treatment of paraoxonase 1 (pon1) related diseases by inhibition of natural antisense transcript to pon1
KR101807323B1 (ko) 2009-06-24 2017-12-08 큐알엔에이, 인크. Ｔｎｆｒ2에 대한 천연 안티센스 전사체의 억제에 의한 종양 괴사 인자 수용체 2(ｔｎｆｒ2) 관련된 질환의 치료
CA2765815A1 (en) 2009-06-26 2010-12-29 Opko Curna, Llc Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene
CA2768947C (en) 2009-07-24 2018-06-19 Opko Curna, Llc Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
EP2462229B1 (de) 2009-08-05 2016-05-11 CuRNA, Inc. Behandlung von durch insulingene bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts gegen ein insulingen
CN102625841A (zh) 2009-08-11 2012-08-01 欧科库尔纳有限责任公司 通过抑制脂连蛋白(adipoq)的天然反义转录物治疗脂连蛋白(adipoq)相关疾病
US8791087B2 (en) 2009-08-21 2014-07-29 Curna, Inc. Treatment of ‘C terminus of HSP70-interacting protein’ (CHIP)related diseases by inhibition of natural antisense transcript to CHIP
CA2771172C (en) 2009-08-25 2021-11-30 Opko Curna, Llc Treatment of 'iq motif containing gtpase activating protein' (iqgap) related diseases by inhibition of natural antisense transcript to iqgap
JP6175236B2 (ja) 2009-09-25 2017-08-09 カッパーアールエヌエー，インコーポレイテッド フィラグリン（ｆｌｇ）の発現および活性の調整によるｆｌｇ関連疾患の処置
KR101823702B1 (ko) 2009-12-16 2018-01-30 큐알엔에이, 인크. 막 결합 전사 인자 펩티다제, 부위 １(ｍｂｔｐｓ１)에 대한 천연 안티센스 전사체의 억제에 의한 ｍｂｔｐｓ１ 관련 질환의 치료
CN102869776B (zh) 2009-12-23 2017-06-23 库尔纳公司 通过抑制肝细胞生长因子(hgf)的天然反义转录物而治疗hgf相关疾病
RU2619185C2 (ru) 2009-12-23 2017-05-12 Курна, Инк. Лечение заболеваний, связанных с разобщающим белком 2 (ucp2), путем ингибирования природного антисмыслового транскрипта к ucp2
WO2011090740A2 (en) 2009-12-29 2011-07-28 Opko Curna, Llc Treatment of nuclear respiratory factor 1 (nrf1) related diseases by inhibition of natural antisense transcript to nrf1
US8962585B2 (en) 2009-12-29 2015-02-24 Curna, Inc. Treatment of tumor protein 63 (p63) related diseases by inhibition of natural antisense transcript to p63
KR101853511B1 (ko) 2009-12-31 2018-06-20 큐알엔에이, 인크. 인슐린 수용체 기질 2 및 전사 인자 ｅ3(ｔｆｅ3)에 대한 천연 안티센스 전사체의 억제에 의한 ｉｒｓ2 관련된 질환의 치료
KR101878501B1 (ko) 2010-01-04 2018-08-07 큐알엔에이, 인크. 인터페론 조절 인자 8 (ｉｒｆ8)에 대한 자연 안티센스 전사체의 저해에 의한 인터페론 조절 인자 8 (ｉｒｆ8) 관련된 질환의 치료
KR101853509B1 (ko) 2010-01-06 2018-04-30 큐알엔에이, 인크. 췌장 발달 유전자에 대한 천연 안티센스 전사체의 억제에 의한 췌장 발달 유전자와 관련된 질환의 치료
CA2786535C (en) 2010-01-11 2019-03-26 Curna, Inc. Treatment of sex hormone binding globulin (shbg) related diseases by inhibition of natural antisense transcript to shbg
JP5981850B2 (ja) 2010-01-25 2016-08-31 カッパーアールエヌエー，インコーポレイテッド ＲＮａｓｅＨ１に対する天然アンチセンス転写物の阻害によるＲＮａｓｅＨ１関連疾患の治療
JP5976548B2 (ja) 2010-02-22 2016-08-23 カッパーアールエヌエー，インコーポレイテッド Ｐｙｃｒ１に対する天然アンチセンス転写物の阻害によるピロリン−５−カルボン酸レダクターゼ１（ｐｙｃｒ１）関連疾患の治療
AU2011232365A1 (en) 2010-03-24 2012-10-25 Rxi Pharmaceuticals Corporation RNA interference in dermal and fibrotic indications
US8980856B2 (en) 2010-04-02 2015-03-17 Curna, Inc. Treatment of colony-stimulating factor 3 (CSF3) related diseases by inhibition of natural antisense transcript to CSF3
WO2011127337A2 (en) 2010-04-09 2011-10-13 Opko Curna Llc Treatment of fibroblast growth factor 21 (fgf21) related diseases by inhibition of natural antisense transcript to fgf21
CA2798218A1 (en) 2010-05-03 2011-11-10 Curna, Inc. Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
TWI531370B (zh) 2010-05-14 2016-05-01 可娜公司 藉由抑制ｐａｒ４天然反股轉錄本治療ｐａｒ４相關疾病
JP5917497B2 (ja) 2010-05-26 2016-05-18 カッパーアールエヌエー，インコーポレイテッド メチオニンスルホキシドレダクターゼａ（ｍｓｒａ）に対する天然アンチセンス転写物の阻害によるｍｓｒａ関連疾患の治療
EP2576783B1 (de) 2010-05-26 2017-11-29 CuRNA, Inc. Behandlung von durch atonal homolog 1 (atoh1) vermittelten erkrankungen durch hemmung des natürlichen antisense-transkripts für atoh1
CN103025873B (zh) 2010-06-23 2018-05-08 库尔纳公司 通过抑制电压门控钠通道α亚基(SCNA)的天然反义转录物而治疗SCNA相关疾病
JP5998131B2 (ja) 2010-07-14 2016-09-28 カッパーアールエヌエー，インコーポレイテッド Ｄｉｓｃｓｌａｒｇｅｈｏｍｏｌｏｇ（ｄｌｇ）ｄｌｇ１への天然アンチセンス転写物の阻害によるｄｌｇ関連疾患の治療
RU2624048C2 (ru) 2010-10-06 2017-06-30 Курна, Инк. Лечение заболеваний, связанных с геном сиалидазы 4 (neu4), путем ингибирования природного антисмыслового транскрипта гена neu4
WO2012054723A2 (en) 2010-10-22 2012-04-26 Opko Curna Llc Treatment of alpha-l-iduronidase (idua) related diseases by inhibition of natural antisense transcript to idua
US10000752B2 (en) 2010-11-18 2018-06-19 Curna, Inc. Antagonat compositions and methods of use
KR102010598B1 (ko) 2010-11-23 2019-08-13 큐알엔에이, 인크. Nanog에 대한 자연 안티센스 전사체의 저해에 의한 nanog 관련된 질환의 치료
RU2620980C2 (ru) 2011-06-09 2017-05-30 Курна, Инк. Лечение заболеваний, связанных с фратаксином (fxn), путем ингибирования природного антисмыслового транскрипта fxn
EA029151B1 (ru) 2011-09-06 2018-02-28 Курна, Инк. ЛЕЧЕНИЕ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С АЛЬФА-СУБЪЕДИНИЦАМИ ПОТЕНЦИАЛЗАВИСИМЫХ НАТРИЕВЫХ КАНАЛОВ (SCNxA), С ПОМОЩЬЮ МАЛЫХ МОЛЕКУЛ
US9308163B2 (en) 2012-02-15 2016-04-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of treating and preventing diseases and disorders of the central nervous system
CN104271142B (zh) 2012-03-01 2017-07-04 福斯特斯特林研究公司 含有α连接蛋白C‑末端(ACT)肽的局部凝胶
WO2013138374A2 (en) 2012-03-15 2013-09-19 Curna, Inc. Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
US20140274872A1 (en) * 2013-03-15 2014-09-18 Coda Therapeutics, Inc. Compositions and treatments based on cadherin modulation
WO2013148736A1 (en) 2012-03-27 2013-10-03 Coda Therapeutics, Inc. Compositions and treatments based on cadherin modulation
SG11201507211YA (en) * 2013-03-11 2015-10-29 Univ North Carolina Compositions and methods for targeting o-linked n-acetylglucosamine transferase and promoting wound healing
US9156896B2 (en) 2013-03-15 2015-10-13 Coda Therapeutics, Inc. Wound healing compositions and treatments
EP3077050B1 (de) * 2013-12-04 2020-10-21 Phio Pharmaceuticals Corp. Verfahren zur behandlung von wundheilung mit chemisch modifizierten oligonukleotiden
CA2940648A1 (en) * 2014-02-25 2015-09-03 Coda Therapeutics, Inc. Treatment of resistant lesions
US20170106047A1 (en) * 2014-06-12 2017-04-20 The Research Foundation For The State University Of New York Methods of using gap junctions as therapeutic targets for the treatment of degenerative disorders of the retina
EA201790434A1 (ru) 2014-08-22 2017-07-31 Окленд Юнисервисиз Лимитед Модуляторы каналов
WO2016037071A2 (en) 2014-09-05 2016-03-10 Rxi Pharmaceuticals Corporation Methods for treating aging and skin disorders using nucleic acids targeting tyr or mmp1
CN116672445A (zh) * 2016-02-26 2023-09-01 德克萨斯大学体系董事会 连接蛋白(Cx)43半通道结合抗体及其用途
JP7495230B2 (ja) 2017-04-28 2024-06-04 オークランド ユニサービシズ リミテッド 処置方法および新規構築物
EP3685824A1 (de) * 2019-01-25 2020-07-29 Breitenbronn-Consulting GbR Zusammensetzung zur verabreichung und freisetzung von oligonukleotiden
WO2023219655A1 (en) * 2022-05-13 2023-11-16 University Of Utah Research Foundation Gja1-20k to limited cardiac arrhythmias

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9425930D0 (en) 1994-12-22 1995-02-22 Procter & Gamble Silicone compositions
US6149904A (en) * 1996-01-31 2000-11-21 The Regents Of The University Of California Method for inhibiting tumor cell growth by administering to tumor cells expressing a nucleic acid encoding a connexin and a pro-drug
EP1464703A3 (de) * 1996-03-07 2004-10-13 Eisai Co., Ltd. Adhäsionsmolekül Occludin vom Hund
WO1998002150A1 (en) * 1996-07-17 1998-01-22 Medtronic, Inc. System for genetically treating cardiac conduction disturbances
CA2273203A1 (en) * 1996-12-02 1998-06-11 Dyad Pharmaceutical Corporation Antisense inhibition of human adhesion molecules
JP4404479B2 (ja) * 1997-12-09 2010-01-27 チルドレンズ・メディカル・センター・コーポレイション 血管内皮増殖因子の可溶性インヒビターおよびその使用
WO2000044409A1 (en) * 1999-01-27 2000-08-03 University College London Formulations comprising antisense nucleotides to connexins
US5998148A (en) * 1999-04-08 1999-12-07 Isis Pharmaceuticals Inc. Antisense modulation of microtubule-associated protein 4 expression

Also Published As

Publication number Publication date
US20070037765A1 (en) 2007-02-15
EP1146908A1 (de) 2001-10-24
JP2013135677A (ja) 2013-07-11
AU2119300A (en) 2000-08-18
US20080249041A1 (en) 2008-10-09
DE60021700D1 (de) 2005-09-08
CA2361251C (en) 2011-03-08
US9193754B2 (en) 2015-11-24
ES2245638T3 (es) 2006-01-16
JP2013136594A (ja) 2013-07-11
DK1621212T3 (da) 2012-03-05
US7902164B2 (en) 2011-03-08
DK2314321T3 (da) 2014-09-08
CA2730386C (en) 2015-08-11
US20130079388A1 (en) 2013-03-28
JP5705890B2 (ja) 2015-04-22
NZ513154A (en) 2004-01-30
US20070060538A1 (en) 2007-03-15
US20070072820A1 (en) 2007-03-29
US20070078103A1 (en) 2007-04-05
CA2361251A1 (en) 2000-08-03
ES2377749T3 (es) 2012-03-30
CY1115521T1 (el) 2017-01-04
CA2730386A1 (en) 2000-08-03
US20070066555A1 (en) 2007-03-22
DK1146908T3 (da) 2005-10-10
AU776512B2 (en) 2004-09-09
PT1621212E (pt) 2012-02-20
EP1621212A1 (de) 2006-02-01
EP2314321A1 (de) 2011-04-27
US20070072819A1 (en) 2007-03-29
US20080221051A1 (en) 2008-09-11
JP2002535377A (ja) 2002-10-22
ES2498745T3 (es) 2014-09-25
EP1621212B1 (de) 2011-11-16
US8314074B2 (en) 2012-11-20
ATE533515T1 (de) 2011-12-15
US7098190B1 (en) 2006-08-29
US20110065770A1 (en) 2011-03-17
JP4994533B2 (ja) 2012-08-08
PT1146908E (pt) 2005-10-31
US7879811B2 (en) 2011-02-01
US7615540B2 (en) 2009-11-10
PT2314321E (pt) 2014-09-26
JP5736397B2 (ja) 2015-06-17
WO2000044409A1 (en) 2000-08-03
EP2314321B1 (de) 2014-06-04
CY1112557T1 (el) 2016-02-10
JP2012041342A (ja) 2012-03-01
DE60021700T2 (de) 2006-06-01
US7919474B2 (en) 2011-04-05
EP1146908B1 (de) 2005-08-03

Similar Documents

Publication Publication Date Title
ATE533515T1 (de) Formulierungen enthaltend antisense nukleotide spezifisch für connexine
EP1041880A4 (de) Verabreichung von arginin zur erzielung eines wohltuenden effektes
US4596812A (en) Methods and solutions for treating male pattern alopecia
DE59911740D1 (de) Topisch anwendbare mittel gegen nagelpilzerkrankungen
MY135988A (en) Additive for improving the water resistance of cosmetic or dermatological formulations
ES2191068T3 (es) Tratamiento profilactico y terapeutico de la sensibilizacion e irritacion de la piel.
BR0204596A (pt) Composição tópica, e, métodos para melhorar a aparência estética da pele, para intensificar a eficácia terapêutica de uma composição tópica para a pele, unha, lábios e/ou cabelo e para intensificar a produção de um constituinte de célula de planta predeterminada
ATE290397T1 (de) Formulierung fur die wundheilung mit menschlichem plasma fibronektin
ATE56862T1 (de) Hautbehandlungszusammensetzung.
EP0471135B1 (de) Haarwuchsmittel
AU2001240940A1 (en) Cosmetic and dermatological composition for psoriatic skin, scalp treatment and care
DK1009425T3 (da) Anvendelse af latens-associeret-peptid til fremstilling af et medikament til forøgelse af sårheling
JP2004500353A5 (de)
FR2865651B1 (fr) Compositions topiques associant des fragments de hyaluronate de sodium et un retinoide utiles en dermatologie cosmetique et medicale
BR0116293A (pt) Composição tópica, e, método para prevenir, melhorar ou tratar a hiperpigmentação da pele
IT1258069B (it) Composizione per uso topico avente attivita' di stimolo per la ricrescita, di rinvigorimento, di prevenzione dell'ingrigimento e di ripigmentazione naturale dei capelli
ES2176495T3 (es) Utilizacion de un antagonista de la bradiquinina, destinada a inducir y/o estimular el crecimiento de los cabellos y/o frenar su caida.
MXPA04012527A (es) Tratamientos para el cabello y las unas usando alcanolaminas.
IE810489L (en) Composition for topical application
WO1994004184A3 (en) Method of decreasing cutaneous senescence
US20180085295A1 (en) Hair Growth Composition
AU3952300A (en) Method to reduce hair loss and stimulate hair regrowth
RU93002420A (ru) Способ лечения раны
BR0011980A (pt) Composiçao cosmética; e uso de uma composição
WO2002098515A3 (en) Topical treatments using alkanolamines

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1146908

Country of ref document: EP